http://44.224.82.126/3-v-biosciences-to-present-at-the-2015-wedbush-pacgrow-healthcare-conference-on-august-12-2015-2/ 2019-09-24T11:48:06+00:00 http://44.224.82.126/fasn-inhibitor-tvb-2640-shows-pharmacodynamic-effect-and-evidence-of-clinical-activity-in-kras-mutant-nsclc-patients-in-a-phase-i-study-poster-presentation-at-aacr-meeting-on-monday-apr-18-2016-100/ 2020-10-19T20:29:53+00:00 http://44.224.82.126/diacylglycerol-metabolism-and-signaling-is-a-driving-force-underlying-fasn-inhibitor-sensitivity-in-cancer-cells-paper-acs-chemical-biology/ 2020-10-28T01:26:26+00:00 http://44.224.82.126/3-v-biosciences-appoints-merdad-v-parsey-md-phd-as-chief-executive-officer/ 2023-05-10T03:30:05+00:00 http://44.224.82.126/james-f-young-joins-3-v-biosciences-board-of-directors/ 2023-05-10T03:30:11+00:00 http://44.224.82.126/3-v-biosciences-appoints-edward-m-connor-jr-md-chief-medical-officer/ 2023-05-10T03:30:18+00:00 http://44.224.82.126/3-v-biosciences-expands-leadership-team-opens-new-facility-and-integrates-operations/ 2023-05-10T03:30:24+00:00 http://44.224.82.126/30v-biosciences-appoints-george-w-kemble-phd-as-chief-scientific-officer/ 2023-05-10T03:30:38+00:00 http://44.224.82.126/3-v-biosciences-promotes-stephen-r-bradyto-chief-business-officer/ 2023-05-10T03:30:39+00:00 http://44.224.82.126/3-v-biosciences-to-present-data-on-hcv-product-candidates/ 2023-05-10T03:31:10+00:00 http://44.224.82.126/3-v-biosciences-presents-positive-preclinical-data-on-hcv-product-candidates-targeting-fasn-at-the-american-association-for-the-study-of-liver-disease-annual-meeting-2012/ 2023-05-10T03:31:10+00:00 http://44.224.82.126/3%e2%80%90v-biosciences-to-present-at-the-seventh-annual-jmp-securities-healthcare-conference/ 2023-05-10T03:31:11+00:00 http://44.224.82.126/3-v-biosciences-closes-preferred-stock-financing-and-designates-novel-host-factor-hepatitis-c-program/ 2023-05-10T03:31:11+00:00 http://44.224.82.126/3-v-biosciences-appoints-douglas-i-buckley-phd-as-vice-president-of-biology/ 2023-05-10T03:31:11+00:00 http://44.224.82.126/3-v-biosciences-commences-patient-dosing-in-phase-1-clinical-study-of-fasn-inhibitor-tvb-2640-in-patients-with-advanced-solid-tumors-first/ 2023-05-10T03:32:09+00:00 http://44.224.82.126/3-v-biosciences-presents-positive-data-for-novel-fasn-inhibitor-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ 2023-05-10T03:32:10+00:00 http://44.224.82.126/3-v-biosciences-names-dr-william-mcculloch-chief-medical-officer/ 2023-05-10T03:32:10+00:00 http://44.224.82.126/3-v-biosciences-completes-20-million-series-c-financing/ 2023-05-10T03:32:10+00:00 http://44.224.82.126/sagimet-biosciences-to-present-additional-biomarker-phase-2-data-on-denifanstat-tvb-2640-in-nash-patients-at-ddw-2022/ 2023-05-10T03:32:37+00:00 http://44.224.82.126/sagimet-biosciences-announces-presentation-of-additional-phase-2-data-on-denifanstat-identifying-a-predictive-metabolic-signature-in-nash-patients-at-easls-international-liver-congress-ilc/ 2023-05-10T03:32:37+00:00 http://44.224.82.126/sagimet-biosciences-announces-oral-presentation-on-denifanstat-at-keystone-symposia-in-nonalcoholic-steatohepatitis-nash/ 2023-05-10T03:32:37+00:00 http://44.224.82.126/sagimet-biosciences-announces-completion-of-patient-enrollment-in-phase-2b-fascinate-2-clinical-trial-with-denifanstat-tvb-2640-a-first-in-class-fatty-acid-synthase-inhibitor-in/ 2023-05-10T03:32:37+00:00 http://44.224.82.126/sagimet-biosciences-announces-appointment-of-david-happel-to-chief-executive-officer-dr-george-kemble-to-transition-to-executive-chairman-role/ 2023-05-10T03:32:37+00:00 http://44.224.82.126/sagimet-biosciences-announces-late-breaking-oral-and-poster-presentations-for-denifanstat-tvb-2640-a-first-in-class-fatty-acid-synthase-inhibitor-in-nash-at-aaslds-the-liver-meeting/ 2023-05-10T03:32:37+00:00 http://44.224.82.126/sagimet-biosciences-announces-positive-interim-phase-2b-clinical-trial-data-with-denifanstat-tvb-2640-a-first-in-class-fatty-acid-synthase-inhibitor-in-moderate-to-severe-non-alcoholic-steatohepa/ 2023-05-10T03:32:37+00:00 http://44.224.82.126/published-results-from-sagimets-fascinate-1-phase-2a-trial-demonstrate-fasn-inhibitor-tvb-2640s-ability-to-significantly-reduce-excess-liver-fat/ 2023-05-10T03:33:16+00:00 http://44.224.82.126/sagimet-biosciences-doses-first-patient-in-fascinate-2-phase-2b-trial-in-nash-patients-with-moderate-to-advanced-fibrosis/ 2023-05-10T03:33:16+00:00 http://44.224.82.126/sagimet-biosciences-doses-first-patient-in-fascinate-2-phase-2b-trial-in-nash-patients-with-moderate-to-advanced-fibrosis-2/ 2023-05-10T03:33:16+00:00 http://44.224.82.126/new-data-from-sagimets-phase-2-fascinate-1-clinical-trial-demonstrate-tvb-2640s-positive-effect-across-patients-with-nash-in-the-u-s-and-china/ 2023-05-10T03:33:16+00:00 http://44.224.82.126/sagimet-biosciences-receives-fast-track-designation-from-u-s-food-and-drug-administration-for-fasn-inhibitor-tvb-2640-in-nash/ 2023-05-10T03:33:17+00:00 http://44.224.82.126/sagimet-to-present-phase-2-data-on-lead-candidate-tvb-2640-at-the-international-liver-congress-2021-easl/ 2023-05-10T03:33:17+00:00 http://44.224.82.126/sagimet-biosciences-appoints-life-sciences-industry-veteran-elizabeth-grammer-to-board-of-directors/ 2023-05-10T03:33:17+00:00 http://44.224.82.126/sagimet-biosciences-raises-80-million-in-crossover-financing/ 2023-05-10T03:33:17+00:00 http://44.224.82.126/fasn-inhibitor-asc40-demonstrates-positive-phase-2-topline-clinical-results-from-china-cohort-of-patients-with-nash/ 2023-05-10T03:33:17+00:00 http://44.224.82.126/sagimet-biosciences-names-dr-eduardo-bruno-martins-as-chief-medical-officer/ 2023-05-10T03:33:17+00:00 http://44.224.82.126/sagimet-announces-positive-topline-results-in-12-week-nash-phase-2-clinical-trial-of-fasn-inhibitor-tvb-2640-2/ 2023-05-10T03:33:45+00:00 http://44.224.82.126/asc40-tvb-2640-phase-2-nash-trial-completed-patient-enrollment-in-china/ 2023-05-10T03:33:45+00:00 http://44.224.82.126/sagimet-announces-positive-topline-results-in-12-week-nash-phase-2-clinical-trial-of-fasn-inhibitor-tvb-2640/ 2023-05-10T03:33:45+00:00 http://44.224.82.126/data-on-sagimets-lead-candidate-tvb-2640-to-be-presented-at-easl-ilc-2020/ 2023-05-10T03:33:46+00:00 http://44.224.82.126/3-v-biosciences-to-present-clinical-and-preclinical-data-for-fasn-inhibitors-at-eortc-nci-aacr-2014/ 2023-05-10T03:34:14+00:00 http://44.224.82.126/3-v-biosciences-announces-presentation-of-first-human-clinical-data-for-lead-oral-fasn-inhibitor-candidate-at-eortc-nci-aacr-2014/ 2023-05-10T03:34:14+00:00 http://44.224.82.126/3-v-biosciences-to-present-at-the-25th-annual-oppenheimer-healthcare-conference/ 2023-05-10T03:34:14+00:00 http://44.224.82.126/3-v-biosciences-announces-closing-of-28-5m-financing-round/ 2023-05-10T03:34:14+00:00 http://44.224.82.126/3-v-biosciences-to-present-data-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-in-boston-ma/ 2023-05-10T03:34:44+00:00 http://44.224.82.126/3-v-biosciences-provides-clinical-update-on-tvb-2640-at-aacr-metabolism-and-cancer-conference/ 2023-05-10T03:34:44+00:00 http://44.224.82.126/3-v-biosciences-to-present-at-the-2015-wedbush-pacgrow-healthcare-conference-on-august-12-2015/ 2023-05-10T03:34:44+00:00 http://44.224.82.126/3-v-biosciences-appoints-rekha-hemrajani-as-chief-financial-officer/ 2023-05-10T03:34:44+00:00 http://44.224.82.126/3-v-biosciences-changes-name-to-sagimet-biosciences-and-closes-25-million-financing/ 2023-05-10T03:35:07+00:00 http://44.224.82.126/ascletis-and-3-v-biosciences-announce-nash-strategic-license-and-series-e-financing/ 2023-05-10T03:35:08+00:00 http://44.224.82.126/3-v-biosciences-commences-dosing-in-phase-2-clinical-study-of-the-fasn-inhibitor-tvb-2640-in-patients-with-nash/ 2023-05-10T03:35:08+00:00 http://44.224.82.126/3-v-biosciences-to-present-data-at-the-american-association-for-the-study-of-liver-diseases-annual-meeting-2016-in-boston-ma/ 2023-05-10T03:35:24+00:00 http://44.224.82.126/3-v-biosciences-to-present-clinical-data-demonstrating-tvb-2640-inhibits-fatty-acid-synthesis-at-the-liver-meeting-2017/ 2023-05-10T03:35:32+00:00 http://44.224.82.126/sagimet-biosciences-to-present-interim-data-from-phase-2b-trial-of-denifanstat-in-nash-at-easl-congress-2023/ 2023-06-22T20:15:01+00:00 http://44.224.82.126/sagimet-biosciences-presents-positive-phase-2b-fascinate-2-clinical-trial-interim-data-for-denifanstat-for-the-treatment-of-nash-at-easl-congress-2023/ 2023-06-23T17:25:38+00:00 /wp-content/uploads/2015/11/Biomarkers_CLIN-002_Poster_-Triple_2015_Clinical-Biomarkers-Poster.pdf#new_tab 2024-08-26T08:55:41+00:00 http://44.224.82.126/wp-content/uploads/2015/11/Poster_Thumbnails_66.jpg /wp-content/uploads/2015/11/EORTC2015_FASN_Preclinical.pdf#new_tab 2024-08-26T08:57:15+00:00 http://44.224.82.126/wp-content/uploads/2015/11/Poster_Thumbnails_67.jpg